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Abstract
Background: In recent years, many immunoregulatory functions have been ascribed to soluble HLA-G (sHLA-G). Since
chemotaxis is crucial for an efficient immune response, we have investigated for the first time the effects of sHLA-G on
chemokine receptor expression and function in different human T cell populations.
Methodology/Principal Findings: T cell populations isolated from peripheral blood were stimulated in the presence or
absence of sHLA-G. Chemokine receptors expression was evaluated by flow cytometry. sHLA-G downregulated expression
of i) CCR2, CXCR3 and CXCR5 in CD4
+ T cells, ii) CXCR3 in CD8
+ T cells, iii) CXCR3 in Th1 clones iv) CXCR3 in TCR Vd2c9 T cells,
and upregulated CXCR4 expression in TCR Vd2c9 T cells. sHLA-G inhibited in vitro chemotaxis of i) CD4
+ T cells towards
CCL2, CCL8, CXCL10 and CXCL11, ii) CD8
+ T cells towards CXCL10 and CXCL11, iii) Th1 clones towards CXCL10, and iv) TCR
Vd2c9 T cells towards CXCL10 and CXCL11. Downregulation of CXCR3 expression on CD4+ T cells by sHLA-G was partially
reverted by adding a blocking antibody against ILT2/CD85j, a receptor for sHLA-G, suggesting that sHLA-G downregulated
chemokine receptor expression mainly through the interaction with ILT2/CD85j. Follicular helper T cells (TFH) were isolated
from human tonsils and stimulated as described above. sHLA-G impaired CXCR5 expression in TFH and chemotaxis of the
latter cells towards CXCL13. Moreover, sHLA-G expression was detected in tonsils by immunohistochemistry, suggesting a
role of sHLA-G in local control of TFH cell chemotaxis. Intracellular pathways were investigated by Western Blot analysis on
total extracts from CD4+ T cells. Phosphorylation of Stat5, p70 s6k, b-arrestin and SHP2 was modulated by sHLA-G
treatment.
Conclusions/Significance: Our data demonstrated that sHLA-G impairs expression and functionality of different chemokine
receptors in T cells. These findings delineate a novel mechanism whereby sHLA-G modulates T cell recruitment in
physiological and pathological conditions.
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Introduction
The classical HLA molecules, also known as HLA-class Ia
molecules, are extremely polymorphic molecules belonging to the
immunoglobulin superfamily [1]. HLA-class Ia molecules are
widely but not ubiquitously expressed. Each HLA class Ia
molecule consists of a single heterotrimer of heavy chain, b2-
microglobulin and a peptide epitope of eight to ten amino acids
embed in the peptide-binding groove of the heavy chain. Most
peptide epitopes are derived from proteins that are synthesized in
the cell, digested by antigen-processing machinery and loaded into
the peptide-binding groove. These peptides are presented to
antigen-specific T cells through the interaction with T-cell
receptor, leading to the killing of cells that are infected with
viruses or intracellular bacteria, or tumor cells[1].
Like HLA class Ia molecules, ‘‘non-classical’’ HLA class Ib
molecules HLA-E, -F, -G and H can associate with b2-
microglobulin(b2m)and canpresent peptides. However,incontrast
with HLA-Ia molecules, class Ib molecules are oligomorphic, with
only few alleles. So far, limited information are available about the
function of HLA-F and HLA-H. HLA-E is able to present peptides
derived from the leader sequence of HLA-class Ia molecules and
HLA-G, giving a ‘‘self signal’’ in cells that express HLA-class I
molecules, and may have a role in autoimmunity[2]. HLA-G is
expressed not only as a cell surface bound molecule, but also as a
soluble moiety in body fluids[3,4,5]. Seven different isoforms
encoded by alternative splicing of the same mRNA, that include
membrane-bound HLA-G1, HLA-G2, HLA-G3, and HLA-G4
and soluble secreted HLA-G5, HLA-G6, and HLA-G7. The major
isoforms of HLA-G present in serum are soluble HLA-G1 and
HLA-G5generatedeitherbysheddingorproteolyticcleavage ofthe
membrane bound isoform or by secretion of a soluble isoform[6].
In normal tissues, HLA-G shows a limited distribution, being
detected only on cytotrophoblast cells (20), thymic epithelial cells
(21), cytokine-activated monocytes (22), mature myeloid and
plasmacytoid dendritic cells (23), and inflamed muscle fibers (24).
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tolerance at the maternal-fetal interface, abrogating the activity of
maternal NK cells against fetal tissue[7]. HLA-G can also present
peptides, but it is still unclear whether these peptides are important
for host defense against pathogens or they act to stabilize the
surface expression of HLA-G[2].
Many immunoregulatory functions have been described in the
last years for HLA-G molecules, in particular on T cells, B cells,
NK cells and antigen presenting cells. HLA-G molecules induce
apoptosis[4], inhibit cell proliferation[8], cytotoxicity[5] and
differentiation[9], and modulate cytokine release[10].
HLA-G binds four receptors, i.e. ILT2 (immunoglobulin (Ig)-
like transcript 2)/CD85j, ILT4 (Ig-like transcript 4)/CD85d,
KIR2D4L (killer inhibitory receptor)/CD158d. ILT2 is broadly
expressed by lymphoid and myeloid cells (T and B cells, NK cells,
dendritic cells, monocytes, macrophages), whereas ILT4 is
myeloid-specific (monocytes, macrophages, dendritic cells), and
KIR2DL4 is expressed only on NK cells. ILT2 and ILT4 interact
with HLA-G, but also with classical HLA class I molecules (with
lower affinity), whereas KIR2DL4 can interact only with HLA-G
[11]. All these receptors are expressed at low levels by resting cells
and are up-regulated on activated cells or in pathological
condition, i.e. viral infection[12].
Moreover, LeMaoult et al. have demonstrated that HLA-G can
up-regulate the expression of its own receptors, since these
receptors were found to be overexpressed in the same pathologies
in which HLA-G is upregulated (i.e. AIDS, tumors, autoimmune
diseases)[13].
CD160 a glycosylphosphatidylinositol-anchored member of the
immunoglobulin superfamily, have been recently described as a
receptor for HLA-G. Fons et al. have demonstrated that
interaction between soluble HLA-G and CD160 on endothelial
cells lead to apoptosis of the latter cells and inhibition of
angiogenesis[14]. However, CD160 is expressed not only on
endothelial cells, but also on NK cells, NKT cells, T cells [14].
Chemotaxis of immune effector cells is a crucial event for the re-
circulation of these cells between lymphoid organs and inflamed
tissues[15]. Chemotaxis is mediated by the interaction of
chemotactic cytokines (chemokines) with their receptors. Chemo-
kines are highly basic proteins of 70–125 amino acids with
molecular masses ranging from 6 to 14 kDa and 20–95%
sequence identity each other, with 4 highly conserved cysteine
residues. Four chemokines subfamilies have been defined accord-
ing to the number of amino acids between the first two cysteine
residues: CC chemokines, CXC chemokines, XC chemokines and
CX3C chemokines. Chemokine receptors are heptahelical G
protein-coupled receptors, with a single polypetide chain of 340–
380 aminoacids spanning 7 times the surface membrane and with
25–80% sequence identity each other. All receptors display an
extracellular acidic N-terminal domain, a serine/threonine-rich
intracellular C-terminal domain, and two disulfide bonds in-
between the N-terminal domain and the second extracellular
loop[16].
Intracellular signalling through G-proteins leads to extension of
lamellipodia through cytoskeletal restructuring, shape changes and
firm adhesion (chemotaxis), release of oxygen radicals, histamine
and cytotoxic granules from granulocytes, and finally modulation
of gene transcription. A given chemokine receptor can be
inactivated at least through two different mechanisms: i) strong
or prolonged chemokine stimulation, leading to uncoupling of G-
proteins, binding of arrestin, and internalization of the receptor, or
ii) stimulation with an unrelated chemoattractant resulting in the
activation of PKA and PKC, phosporylation of the receptor and
its inactivation without internalization[17]. Chemokine receptor
expression can be modulated by pro-inflammatory (i.e. LPS, TNF,
IL-1, IFN-c) and anti-inflammatory (glucocorticoid hormones, IL-
10) stimuli, and by cytokines such as IL-4 and IL-13, leading to a
modulation of immune cells recruitment at sites of infection and
inflammation[18].
So far, no information is available on possible effects of sHLA-G
molecules (and other HLA-I molecules) on chemotaxis of immune
effector cells.
We have investigated this issue on different T cell populations,
not only on classical CD4
+ and CD8
+ T cells, but also on TCRcd
+
T cells and on follicular helper T cells (TFH).
TCRcd T cells circulate in peripheral blood (3–5% of PBMNC)
and express a peculiar TCR composed of c and d chains, that
recognize phosphoantigens. Most circulating TCRcd T cells show
the Vd2c9 rearrangement[19]. TFH are a small subset of TCR ab
T cells present in peripheral blood[20] and secondary lymphoid
organs[21]. These cells, that express CXCR5 and ICOS, gain
access to the germinal center of secondary lymphoid follicles where
they exert a potent helper function for B cell differentiation to
antibody secreting cells through IL-21 production[22].
Our data describe a novel immunoregulatory property of
sHLA-G molecules, based on the inhibition of chemokine-driven
migration of different T cell populations together with downreg-
ulation of the expression and function of selected chemokine
receptors on these cells.
Results
Soluble HLA-G impairs the expression of different
chemokine receptors in different T cell populations
We first evaluated by flow cytometry the expression of a panel of
CC- and CXC-chemokine receptors in the two major subsets of
circulating T lymphocytes, CD4
+ and CD8
+ T cells. These
receptors were selected on the ground of their physiological
relevance[23]. Cells were polyclonally stimulated with anti-CD3
mAb, anti-CD3/CD28 coated beads or PHA, in the presence or
absence of sHLA-G. All these stimuli produced superimposable
results. Therefore, from now onwards, all the experiments
described will be those performed using anti-CD3 mAb. The
effect of sHLA-G on chemokine receptor expression was lower on
resting T cells (not shown).
As shown in Figure 1, panel A, sHLA-G treatment significantly
downregulated the expression of CXCR5 (mean %6SD:
23,62610,7 vs 13,4668,8, p=0.01), CCR2 (mean %6SD:
964,7 vs 2,9561,9, p=0.01) and CXCR3 (mean %6SD:
58,31612,3 vs 24,6867,3, p=0.0029) in CD4+ T cells. In
CD8+ T cells, sHLA-G treatment significantly downregulated
CXCR3 expression (mean %6SD: 63,82615,3 vs 22,08613,1,
p=0.0092) (Fig. 1, panel B). Mean results from five different
experiments 6SD are shown in Figs. 1C and 1D).
Next, we investigated the effects of sHLA-G on three polarized
subsets of CD4+ T cells, i.e. Th1, Th2 and Th17 cells. These
subsets were identified by intracellular staining and flow
cytometric analysis according to cytokine production profiles
(not shown). In particular, Th1 and Th2 cell clones were .95%
IFN-c
+/IL-4
2 and .95% IFN-c
2/IL-4
+, respectively. Bulk Th17
cells enriched from PBMNC were .50% IL17
+. Chemokine
receptor expression in the latter cells was analyzed by flow
cytometry gating on cells expressing IL-17A. All these T cell
subsets were stimulated in the presence or absence of sHLA-G,
and the expression of distinctive chemokine receptors was assessed
by flow cytometry[24].
Among Th1-associated chemokine receptors, sHLA-G signifi-
cantly downregulated the expression of CXCR3 (mean
HLA-G and T Cell Chemotaxis
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whereas CCR5 and CXCR6 were not affected (Fig. 2, panel A).
The expression of three Th2-associated chemokine receptors,
CCR3, CCR4 and CCR8 was not affected by sHLA-G in Th2
clones (Fig. 2, panel B). In Th17 T cells, sHLA-G treatment did
not modulate expression of CCR6 or CCR7, two Th17 associated
chemokine receptors (Fig. 2, panel C). Mean results from five
different experiments 6SD are shown in Figs. 2D, E and F.
We next investigated modulation of a wide panel of CC- and
CXC- chemokine receptors in TCR Vd2c9 T cells by sHLA-G
(Fig. 2, panel G). A significant up-regulation of CXCR4 (mean
%6SD: 14,4162,6 vs 3766,5 p=0.007) was detected, whereas
CXCR3 was significantly downregulated (mean %6SD:
78,0960,3 vs 26,663,3, p,0.0001). Mean results from five
different experiments 6SD are shown in Fig. 2, panel H).
Chemotaxis of different T cell populations is dampened
by soluble HLA-G treatment
The above T cell populations but Th2 and Th17 cells were next
subjected to in vitro migration assays using ligands of the chemokine
receptors modulated by sHLA-G treatment.
As shown in Fig. 3, panel A, sHLA-G treatment significantly
dampened the chemotaxis of CD4
+ T cells towards i) two ligands
of CCR2, i.e. CCL2 (migration index 2,9 vs 0,7, p=0.033) and
CCL8 (migration index 2 vs 0, p=0.048) and ii) two ligands of
CXCR3, i.e. CXCL10 (migration index 13,77 vs 2,21, p,0,0001)
and CXCL11 (migration index 47,40 vs 14,55, p=0,012). No
chemotaxis of CD4
+ T cells was observed towards CXCL13, the
unique ligand of CXCR5, irrespective of the cells had been treated
or not with sHLA-G (data not shown).
CD8+ T cell chemotaxis towards CXCL10 and CXCL11 was
dampened by sHLA-G treatment, as shown in Fig. 3, panel B
(migration index 16,77 vs 2,54, p=0,001 and 44,37 vs 15,33,
p=0,002, respectively).
Fig. 3, panel C shows that chemotaxis of Th1 T cell clones
towards CXCL10 was significantly reduced by sHLA-G treatment
(migration index 3,73 vs 0,93, p=0,03).
As shown in Fig. 3, panel D, TCR Vd2c9 T cell chemotaxis
towards CXCL10 and CXCL11 was significantly downregulated by
sHLA-G (migration index 2,53 vs 0,02, p=0,02 and 2,96 vs 0,52,
p=0,0024, respectively). Conversely, chemotaxis towards CXCL12,
the ligand of CXCR4, was not affected by sHLA-G treatment.
Figure 1. Modulation of chemokine receptors expression in different T cell populations by sHLA-G. Representative histograms of FACS
analysis of chemokine receptor expression on CD4
+ T cells (panel A) and CD8
+ T cells (panel B) stimulated with anti-CD3 monoclonal antibody in
the presence or absence of sHLA-G (100 ng/ml). Dark profile indicated staining with specific mAb, whereas open profile indicated staining with
isotype-matched mAb. Mean and standard deviation of five different experiments is indicated. Histograms show mean of % of positive cells and
standard deviation of five experiments performed on CD4+ T cells (panel C) and CD8+ T cells (panel D). Grey bars indicate cells stimulated in the
presence of sHLA-G, white bars indicated cells stimulated with medium alone. Statistical analysis was performed using t test. P values are indicated
where the difference is significant.
doi:10.1371/journal.pone.0011763.g001
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ligand of CCR7 (which was not modulated by sHLA-G) was not
inhibited by sHLA-G (Figure 3 panel A,B,C and D).
sHLA-G is expressed in secondary lymphoid follicles and
impairs in vitro chemotaxis of TFH cells through
downregulation of CXCR5 expression
All T cell populations here investigated recirculate from
peripheralbloodtosecondarylymphoidorgans.sHLA-Gissecreted
by different cell types, such as monocytes, dendritic cells and
endothelial cells and is detected in sera from normal donors[25].
TFH cells display an unique homing pattern to secondary
lymphoid organs where they are attracted to the germinal centres
of secondary lymphoid follicles by a gradient of CXCL13[26].
We evaluated by flow cytometry the expression of two
distinctive chemokine receptors, i.e. CXCR5 and CCR7, in TFH
cells stimulated in presence or absence of sHLA-G. As shown in
Fig. 4, panel A, CXCR5 but not CCR7 expression was
significantly dampened by sHLA-G treatment (mean %6SD:
91,862,7 vs 19611,6, p=0.0013). Mean results from five
different experiments 6SD are shown in Fig. 4, panel B.
Chemotaxis of TFH cells towards CXCL13 was significantly
dampened by sHLA-G treatment (migration index 5,35 vs 0,
p=0.03), whereas migration towards CCL21, a ligand of CCR7,
was not (Figure 4, panel C).
To investigate the physiological relevance of our findings, we
next evaluated the expression of HLA-G in tonsil tissue sections by
immunohistochemical staining with an anti HLA-G1/G5 mAb. As
shown in Fig. 4, panel D and E, numerous HLA-G1/G5
+ cells
were detected in germinal centres and sub-epithelial areas
(arrows), whereas such cells were virtually absent from the
follicular mantle of secondary lymphoid follicles. These findings
suggest that trafficking of TFH cells in germinal centres may be
physiologically modulated by sHLA-G.
Figure 2. Modulation of chemokine receptors expression in T helper cells and TCR Vd2c9 T cells by sHLA-G. Representative histograms
of FACS analysis of chemokine receptor expression on CD4
+ Th1 clones (panel A), CD4
+ Th2 clones (panel B), Th17 cells (panel C) and TCRcd T cells
(panel G) stimulated with anti-CD3 monoclonal antibody in the presence or absence of sHLA-G (100 ng/ml). Dark profile indicated staining with
specific mAb, whereas open profile indicated staining with isotype-matched mAb. Mean and standard deviation of five different experiments is
indicated. Histograms show mean and standard deviation of five experiments performed on CD4
+ Th1 clones (panel D), CD4
+ Th2 clones (panel E),
Th17 cells (panel F) and TCRcd T cells (panel H). Grey bars indicate cells stimulated in the presence of sHLA-G, white bars indicated cells stimulated
with medium alone. MRFI values are indicated in Panel D and E. % of positive cells is indicated in Panel F and H. Statistical analysis was performed
using t test P values are indicated where the difference is significant.
doi:10.1371/journal.pone.0011763.g002
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mediated inhibition of T cell chemotaxis
The expression of three receptors for sHLA-G on the T cell
surface was next investigated by flow cytometry. As shown in
Fig. 5, panel A, all T cell fractions tested expressed CD160 (MRFI
range 2,28–20,86). The expression of the inhibitory receptor
ILT2/CD85j differed among the following T cell populations: i)
high expression in CD8
+ T cells and TCRcd
+ T cells (MRFI range
19,75–77,9), ii) intermediate expression in CD4
+ T cells (MRFI
range 7,11–12,4) and iii) low expression in TFH cells (MRFI range
1,4–1,47). Expression of ILT4/CD85b was low in all T cell subsets
(Fig. 4, panel A). The expression of all receptors was lower in
polarized T-helper cells (CD160 MRFI range 1,31–1,63; ILT2
MRFI range 1,03–1,19; ILT4 range 1,08–1,16; Fig. 5 panel B).
The expression of the sHLA-G receptors investigated was not
modulated by sHLA-G treatment (data not shown).
To assess the role of ILT2/CD85j in the inhibition of T cell
chemotaxis by sHLA-G, we performed five experiments in which
CD4
+ T cells were stimulated, and blocking antibodies against
ILT2/CD85j or ILT4/CD85b, respectively, or isotypic control
were added. CXCR3 expression was evaluated by flow cytometry
as read-out of the experiment since this receptor was consistently
downregulated by sHLA-G in different T cell populations.
As shown in Fig. 5, panel C, inhibition of CXCR3 expression on
CD4
+ T cells by sHLA-G was significantly reverted by adding a
blocking mAb against ILT2/CD85j, as compared with isotypic control
(% of inhibition 31,46 vs 47,55, p=0,0052); conversely, no effect was
observed in the presence of a blocking mAb against ILT4/CD85b.
These data indicated that sHLA-G inhibited T cell chemokine
receptor expression by interacting mainly with ILT2/CD85j,
although other sHLA-G receptor(s) are likely involved.
This conclusion was reinforced by additional experiments
performed with an agonistic mAb F270 (kindly gifted by
Dr.Daniela Pende) specific for ILT2/CD85j. CXCR3 expression
on CD4
+ T cells was dampened by treatment with anti-ILT2/
CD85j agonistic mAb mimicking the results obtained upon sHLA-
G treatment (mean MRFI6SD: isotype control 9.360.95; anti-
ILT2/CD85j mAb 2.2160.47; p=0.022). Fig. 5, panel D shows a
representative experiment out of three performed. Mean values
and standard deviations are indicated.
Pathways involved in sHLA-G driven intracellular
signaling in T cells
The signaling pathways modulated by sHLA-G in stimulated
CD4
+ T cells was next investigated by Western-blot analysis of a
panel of housekeeping and phosphorylated (p) proteins involved in
HLA-G/ILT2 signaling[27]. These proteins have been chosen on
the basis of data obtained by Durrbach et al (abstract at HLA-G
International Conference, Paris 2009) and Naji et al. (J Exp Med,
submitted) on B lymphocytes.
Figure 3. Modulation of chemotaxis of different T cell populations by sHLA-G. CD4+ T cells (panel A), CD8+ T cells (panel B), Th1 cell
clones (panel C) and TCR Vd2c9 T cells (panel D) were stimulated with anti-CD3 monoclonal antibody in the presence (grey bars) or absence (white
bars) of sHLA-G (100 ng/ml) and then subjected to in vitro chemotaxis assay using Transwell system. Chemokines were tested at 300 ng/ml. Results
are expressed as migration index (number of migrated cells/number of dispensed cells*100). Mean of five different experiments 6 SD is shown.
Statistical analysis was performed using t test. P values are indicated where the difference is significant.
doi:10.1371/journal.pone.0011763.g003
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Fig. 6, panel A. Quantification of proteins have been performed by
densitometry autoradiography films. Results are summarized in
Table 1.
p-Stat5 and p-p70 s6k, but not Stat5 and p70 s6k, respectively,
were strongly downregulated by sHLA-G treatment. Up-regula-
tion of p-SHP-2 and p-b-arrestin, but not of the corresponding
housekeeping proteins, was detected in sHLA-G treated CD4
+ T
cells (Fig. 6, panel A). sHLA-G treatment decreased levels of p-
PKC-d and increased those of the corresponding housekeeping
protein (Fig. 6, panel A).
Expression of GSK-3b and mTOR, but not that of their
phosphorylated forms, was downregulated by sHLA-G. Expres-
sion of either p-Stat3 or Stat3 was unaffected by sHLA-G (Fig. 6,
panel A).
Finally, no modulation of AKT (MRFI 189,97 vs 157) and p-
AKT (MRFI 1,41 vs 1,25) expression by sHLA-G treatment was
detected by flow cytometry. A representative experiment out of
three performed is shown in Fig. 6, panel B.
Our data indicated that multiple intracellular signaling
pathways in T lymphocytes can be affected by sHLA-G treatment.
We next analyzed whether hyper- phosphorylation of SHP-2
phosphatase was a crucial event in sHLA-G induced downreg-
ulation of chemokine receptors. Again, CXCR3 expression was
analysed by flow cytometry as read-out of the experiments.
Fig. 6, panel C, shows a representative experiment out of the
three performed in which downregulation of CXCR3 expres-
sion in CD4
+ T cells induced by sHLA-G was completely
reverted when CD4
+ T cells were pre-treated with PHPS1, a
specific inhibitor of SHP-2[28] (mean MRFI6SD: CTR
17,560,5; HLA-G 2.4660,5; HLA-G + PHPS1 5,3960,53;
p=0,05).
Discussion
In this paper, we describe a novel mechanism of immune
modulation operated by sHLA-G molecules. This mechanism
involves phenotypic downregulation of some chemokine receptors
Figure 4. Effects of sHLA-G on follicular helper T cells (TFH) from human tonsil. Panel A. Representative histograms of FACS analysis of
chemokine receptor expression on TFH stimulated with anti-CD3 monoclonal antibody in the presence or absence of sHLA-G (100 ng/ml). Dark profile
indicated staining with specific mAb, whereas open profile indicated staining with isotype-matched mAb. Mean and standard deviation of five
different experiments is indicated. Panel B. Histograms show mean of % positive cells and standard deviation of five experiments performed on TFH.
Grey bars indicate cells stimulated in the presence of sHLA-G, white bars indicated cells stimulated with medium alone. Statistical analysis was
performed using t test. P values are indicated where the difference is significant. Panel C. TFH were stimulated with anti-CD3 monoclonal antibody in
the presence (grey bars) or absence (white bars) of sHLA-G (100 ng/ml) and then subjected to in vitro chemotaxis assay using Transwell system.
Chemokines were tested at 300 ng/ml. Results are expressed as migration index (number of migrated cells/number of dispensed cells*100). Mean of
five different experiments 6 SD is shown. Statistical analysis was performed using t test. P values are indicated where the difference is significant.
Panel D. Tonsil tissue sections were stained with an anti-HLA-G1/G5 mAb as detailed in Materials and Methods. Continuous arrows indicated sHLA-
G
+ cells in germinal centre. Dotted arrows indicate sHLA-G
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chemotaxis of the latter cells to the respective ligands.
CD4
+ T cells orchestrate adaptive immune responses by
promoting B cell activation and differentiation to antibody
secreting cells, maturation of cytotoxic T cells, activation of NK
cells and macrophages. Activated CD4
+ T cells are attracted by
chemokine gradients to inflammatory sites where they migrate
across endothelial vessels[29]. This latter process involves CD4
+ T
cell expression of different adhesion molecules, such as selectins
and integrins, and different chemokine receptors[29]. Under
polarizing antigenic stimulation, activated naı ¨ve CD4
+ T cells
differentiate into discrete subsets with distinctive patterns of
cytokine production and effector functions[24]. These subsets
display different chemotactic properties in vitro and in vivo related to
the expression of distinctive sets of chemokine receptors[30].
In particular, i) Th1 T cells express CXCR3, CCR5 and
CXCR6 and accumulate in inflammatory sites following gradients
of chemokines such as CCL2 and CXCL10[31]; ii) Th2 T cells
express CCR3, CCR4 and CCR8 and accumulate in inflamma-
tory sites following gradients of chemokines such as CCL17 and
CCL22[31] and iii) Th17 cells express CCR6 and CCR7 and are
attracted by CCL20 and CCL19 or CCL21, respectively[32].
Here we show that CXCR3 expression was strongly downreg-
ulated by sHLA-G in total CD4+ T cells and Th1 cell clones, and
accordingly chemotaxis of these cell fractions to the CXCR3
ligands CXCL10 and CXCL11 was significantly impaired by
sHLA-G. In contrast, sHLA-G treatment did not affect CCR3,
CCR4 or CCR8 expression by Th2 cell clones and CCR6 or
CCR7 expression by Th17 cells.
Failure of sHLA-G to modulate Th2 cell associated chemokine
receptors is consistent with the recent demonstration of high levels
of sHLA-G in sera from allergic patients supporting the hypothesis
that sHLA-G contributes to maintain Th2-polarized immune
responses[33].
Th17 cells play a pivotal pathogenic role in mouse models of
human rheumatoid arthritis[34], multiple sclerosis[35] and in
Figure 5. Expression and function of sHLA-G receptors in different T cell populations. Panel A. FACS analysis of the expression of sHLA-G
receptors ILT2/CD85j, ILT4/CD85b and CD160 in CD4+ T cells (white bars), CD8+ T cells (black bars), TCR Vd2c9 T cells (light grey bars) and TFH cells
(grey bars). Results are expressed as MRFI. Mean of five different experiments 6 SD is shown. Panel B. FACS analysis of the expression of sHLA-G
receptors ILT2/CD85j, ILT4/CD85b and CD160 in Th1 cell clones (white bars), Th2 cell clones (grey bars) and Th17 cells (black bars). Results are
expressed as MRFI. Mean of five different experiments 6 SD is shown. Panel C. Blocking experiments were performed with CD4+ T cells stimulated
with anti-CD3 mAb in the presence or absence of sHLA-G (100 nM) by adding anti-ILT2 or anti-ILT4 blocking mAbs, or isotype-matched control mAb.
Percentage of CXCR3
+ cells was evaluated by flow cytometry. Results are expressed as % of inhibition calculated as follows: [12(% of positive cells
with sHLA-G/% of positive cells w/o sHLA-G) 6100]. Histograms show mean and standard deviation of five different experiments performed.
Statistical analysis was performed using t test. P value is shown where the difference is significant. Panel D. Representative histogram of FACS
analysis of CXCR3 expression in CD4
+ T cells stimulated with anti-CD3 mAb in the presence of anti-ILT2/CD85j agonist mAb (clone #F270) or isotype-
matched control. A representative experiment out of three performed is shown. Dark profile indicated staining with specific mAb, whereas open
profile indicated staining with isotype-matched mAb. Mean of MRFI values and standard deviations are indicated. Statistical analysis was performed
using Mann-Whitney test. P values are indicated where the difference is significant.
doi:10.1371/journal.pone.0011763.g005
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Th17 cell attraction to sites of inflammation. Here we show for the
first time that sHLA-G does not alter CCR6 expression in Th17
cells, suggesting that CCR6 driven chemotaxis is not amenable to
inhibition mediated by sHLA-G.
We have here addressed also the effects of sHLA-G molecules
on two populations of cytotoxic T cells, i.e. CTL and TCR Vd2c9
T cells, both of which control infections mediated by intracellular
pathogens. In particular, CTL are specialized in the protection
from viral infections[37], while TCR Vd2c9 T cells are mainly
involved in protection from mycobacterial infections[38]. In
analogy to that observed with CD4
+ T cells and Th1 cell clones,
both CTL and TCR Vd2c9 T cells showed strong downregulation
of CXCR3 by sHLA-G associated with inhibition of chemotaxis to
CXCL10 and CXCL11. The finding that CXCR4 expression was
up-regulated by sHLA-G in TCR Vd2c9 T cells without an
increase of the migration of the latter cells towards CXCL12 was
not surprising, since several examples in the literature have shown
that modulation of chemokine receptor expression is not always
coupled with changes in receptor function[39].
sHLA-G is detected in sera from normal donors and is
physiologically produced by myeloid cells such as monocytes and
dendritic cells, as well as by activated endothelial cells[25].
Furthermore, serum sHLA-G concentration is modulated in
different pathological conditions. In particular, serum sHLA-G
levels increase in patients with solid and haematological tumors,
allergy and viral infections, and decrease in patients with auto-
immune disorders[25]. Moreover, the concentration of sHLA-G
tested in our experiments in vitro (100 ng/ml) was observed in sera
from patients with solid and haematological malignancies, whereas
concentration of sHLA-G in sera healthy subjects is in general
below 20 ng/ml[40,41]. Therefore, our results may have patho-
Figure 6. Western Blot analysis of sHLA-G intracellular signalling pathway. Panel A. Western blot analysis of total protein extracts from
CD4+ T cells stimulated with anti-CD3 mAb in the presence or absence of sHLA-G (100 nM). Housekeeping proteins are shown in the left column,
whereas phosphorylated protein are shown in the right column. GAPDH was evaluated as control. Molecular weight (KDa) for each band is indicated
on the right. Panel B. Representative histogram of FACS analysis of Akt and p-Akt expression in CD4+ T cells stimulated with anti-CD3 mAb in the
presence or absence of sHLA-G (100 ng/ml). A representative experiment out of three performed is shown. Dark profile indicated staining with
specific mAb, whereas open profile indicated staining with isotype-matched mAb. MRFI values are indicated. Panel C. Representative histogram of
FACS analysis of CXCR3 expression in CD4
+ T cells stimulated with anti-CD3 mAb in the presence of medium alone, sHLA-G (100 ng/ml) and sHLA-G
plus 10 mM PHPS1 (specific inhibitor of SHP-2 phosphatase). A representative experiment out of three performed is shown. Dark profile indicated
staining with specific mAb, whereas open profile indicated staining with isotype-matched mAb. Mean of MRFI values and standard deviations are
indicated. Statistical analysis was performed using Mann-Whitney test. P values are indicated where the difference is significant.
doi:10.1371/journal.pone.0011763.g006
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G serum levels may translate into modulation of T cell migration
to inflamed tissues. In this connection, we have demonstrated that
CXCR3 is the main target of sHLA-G mediated inhibition in
different T cell populations. CXCR3, together with CCR5,
controls Th1 cell migration[42] and is therefore involved in a
broad spectrum of functional activities of these cells. Th1 cells
collaborate with TCR Vd2c9 T cells in the control of
mycobacterial infections[43]. Therefore, it is tempting to speculate
that sHLA-G, by dampening CXCR3 mediated chemotaxis,
modulates the recruitment of these cell populations to granulo-
matous mycobacterial lesions, perhaps limiting excessive tissue
damage. Likewise, in the course of viral infections, attraction of
CTL to infected tissues by CXCR3 ligands may be modulated by
sHLA-G whose serum levels are increased in patients with
different types of viral infection.
Another implication of our results deals with anti-tumor
immune responses in which both CTL and TCR cd T cells play
important roles. Attraction of these cells to the tumor mass is
operated in part by CXCR3 ligands expressed in variable amounts
in the tumor microenvironment by tumor cells or stromal
cells[44]. Since sHLA-G levels are strongly increased in many
malignancies, dampened recruitment of CTL and TCR cd T cells
to the tumor site is likely to take place in vivo and provide a novel
mechanism of sHLA-G related immunosuppression.
Several examples in literature support our data. It has been
reported that CXCR3 is downregulated in several pathological
conditions, in which serum sHLA-G levels are increased, such as
allergy[45], T cell lymphoma[46]and multiple sclerosis [47].
Conversely, CXCR3 has been found to be upregulated in diseased
associated with decerased levels of serum sHLA-G, such as
rheumatoid arthritis and lupus [48].
Here we show for the first time that CXCR5 expression and
CXCL13 driven chemotaxis were strongly downregulated by
sHLA-G in TFH cells, a subset of CD4
+ cells coexpressing CXCR5
and ICOS that circulate from peripheral blood to secondary
lymphoid organs, that may be developmentally related to Th1,
Th2 or Th17 cells[49]. TFH cells exert a potent helper function for
centrocyte differentiation to plasma cells in the light zone of the
GC, where we detected expression of sHLA-G molecules that was
also observed in the subepithelial area of tonsil.
Taken together, these findings support the conclusion that
migration of TFH cells in the light zone of the germinal centre may
be modulated by a gradient of sHLA-G and this can in turn
interfere in TFH-dependent plasma cell differentiation. Based upon
recent studies of dynamic imaging of GC cell trafficking in mice, it
has been proposed that positive selection of GC B cells depends
not only on recognition of antigen presented by follicular dendritic
cells, but also on competition for help provided by TFH cells[50].
Thus, in principle, modulation of CXCR5 expression and function
by sHLA-G may impact indirectly on GC B cell positive selection.
sHLA-G mediated inhibition of T cell chemokine receptor
expression and chemotaxis was found to depend mainly on the
inhibitory receptor ILT2/CD85j. The signalling pathway initiated by
sHLA-G interaction with ILT2/CD85j involved modulation of
phosphorylation of SHP-2, Stat5 and p70 s6k. sHLA-G induced
over-phosphorylation of SHP-2 together with reduced phosphorylation
of Stat5. SHP-2 is a tyrosine phosphatase that upon phosphorylation
by ligand-stimulated inhibitory receptors such as ILT2/CD85j and
ILT4/CD85b can de-phosphorylate and inactivate Stat5, leading to
reduced transcription of several[51] genes including some implicated in
cell motility[52]. Indeed, we demonstrated that SHP-2 plays a pivotal
role in sHLA-G induced downregulation of T cell CXCR3 using the
specific SHP-2 inhibitor PHPS1[28].
Numerous signalling pathways converge on p70 s6k that, upon
phosphorylation, participate in the control of cell cycle progres-
sion[53]. We also demonstrated that sHLA-G induced over-
phosphorylation of b-arrestin, that in its phosphorylated form
binds chemokine receptors and promotes their internalization,
thus preventing further interactions with their ligands[54].
Surprisingly, sHLA-G modulated expression of the housekeeping
but not the phosphorylated mTOR, GSK-3b and PKC-d proteins.
The functional significance of these findings is unknown.
The main findings of this study have been summarized in
Figure 7.
In conclusion, we have shown that sHLA-G performs a novel
immunomodulatory effect on T cells, downregulating the
expression and function of chemokine receptors. Such inhibition
can affect the recirculation of T lymphocytes between peripheral
blood, secondary lymphoid organs and inflamed tissues, leading to
important repercussions on their effector functions.
Materials and Methods
HLA-G1/G5 production
Recombinant HLA-G1/G5 protein was produced in the human
lymphoblastoid cell line 721.221.G1 (kindly provided by Dr.
Francesco Puppo, DIMI, Genoa) by transfection of the 721.221
parental cell line with human HLA-G1 cDNA[55].
Supernatants were collected from the 721.221.G1 cell line after
72 h culture in RPMI 10% FBS at 37uC and 5% CO2, and
subsequently purified using MEM-G/9 monoclonal antibody and
goat anti-mouse beads (Immunotech, Praha, Czech Republic).
Soluble HLA-G was quantified by HLA-G1/G5 specific ELISA.
sHLA-G ELISA was performed using MaxiSorp Nunc-Immuno
96 microwell plates (Nunc A/S, Roskilde, Denmark) coated
overnight at 4uC with mAb MEM-G/9 (Exbio Praha, Czech
Republic; 10 mg/ml) in 0.001 M PBS, pH 7.4 (EuroClone SpA,
PV, Italy). After three washes with PBS 0.05% Tween 20 (washing
buffer), plates were saturated with 200 ml/w of PBS 2% BSA
(Sigma, St.Louis, MO, USA) for 30 min at RT.
100 ml of test samples or standard (serial dilutions of calibrated
721.221.G1 cell line supernatant) were added to each well and
incubated at RT for 1 h. Plates were washed three times with
washing buffer, and then incubated with 100 ml/well of biotinylated
Table 1. Quantification of proteins.
ctr SD sHLA-G SD change % FOLD
p-STAT5 1,103 0,137 0,650 0,155 20,453 241,09
p-b-arrestin 0,860 0,136 1,053 0,054 0,193 +22,48
p-SHP-2 0,123 0,019 1,610 0,401 1,487 +1205,41
GSK-3-b 1,697 0,334 0,157 0,157 21,540 290,77
PKC-d 0,433 0,095 1,160 0,404 0,727 +167,69
mTOR 1,513 0,621 0,000 0,000 21,513 2100,00
p-p70 s6k 1,590 0,067 0,583 0,099 21,007 263,31
Densitometry of autoradiography films was performed and relative density (RD)
was calculated for control (ctr) and sHLA-G as follows: (density of specific band/
density of GAPDH band). Change induced by sHLA-G was calculated as follows:
(RD ctr-RD sHLA-G). % fold change induced by sHLA-G treatment was calculated
as follows: [(RD sHLA-G - RD ctr)21/RD ctr 6100]. RD, change and % fold
change values are indicated only for proteins modulated by sHLA-G treatment.
Mean values and standard deviation (SD) of three different experiments are
shown.
doi:10.1371/journal.pone.0011763.t001
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by Dr. Soldano Ferrone). After three washes, plates were incubated
at RT for 1 h with streptavidin-horse radish peroxidase (GE
Healthcare, Chalfont St. Giles, United Kingdom) 1:4000 in PBS
0.1% Tween 20, 0.1% BSA, for 1 h at RT. After three additional
washes, plates were incubated with 39-39-59-59 Tetramethylbenzi-
dine (TMB, Sigma) for 5 min at RT. H2SO4 5 M (100 ml/w) was
then added, and optical densities were measured at 450 nm.
The assay’s lowest threshold was 1,95 ng/ml of sHLA-G. Each
sample was tested in duplicate.
Cell isolation and culture
The study was approved by the Ethical Committee of the G.
Gaslini Institute, Genoa, Italy. Surgically removed tonsils and
normal peripheral blood (PB) samples were obtained following
written informed consent. Mononuclear cells (MNC) were isolated
by Ficoll-Hypaque (Sigma) density gradient.
CD4
+ and CD8
+ T cells were isolated from PB samples using
anti-CD4 or anti-CD8 microbeads (Myltenyi Biotec, Bergisch
Gladbach, Germany) following manufacturer’s protocol.
T cell clones were generated by cloning at limiting dilution as
previously described[56].
Th1 T cell clones were obtained from normal donors’ PBMNC after
stimuation with Candida Albicans bodies for 6 days as reported[57]. Th2
T cell clones were obtained from PBMNC of donors with allergic
sensistization to Dermatophagoides Pteronissinus (DP) after stimulation with
DP extract (Stallergenes, France) 20 mg/ml for 6 days as reported[57].
After stimulation, T cell blasts were separated using PERCOLL (GE
Healthcare) density gradient, and were then expanded in RPMI 10%
FBS +200 U/ml IL-2 (Chiron, Milano, Italy). Th17 T cells were
obtained from normal donors’ PBMNC using Th17 expansion kit
(Myltenyi Biotec) following manufacturer’s protocol.
TFH cells were isolated from human tonsils mononuclear cells
by immunomagnetic selection of ICOS
+ T cells, using anti-ICOS
Figure 7. Summary of data. Panel A. Table summarized data obtained on the modulation of chemokine receptors expression in different T cell
populations. Upward arrows indicated upmodulation of the receptors. Downward arrows indicated downmodulation of the receptors. Panel B.
Histogram summarized data obtained in Western Blot analysis on CD4 T cells stimuated in the presence or absence of sHLA-G. Densitometry of
autoradiography films was performed and relative density (RD) was calculated for control (ctr) and sHLA-G as follows: (density of specific band/
density of GAPDH band). Change induced by sHLA-G was calculated as follows: (RD ctr-RD sHLA-G). % fold change induced by sHLA-G treatment was
calculated as follows: [(RD sHLA-G - RD ctr)-1/RD ctr 6100].
doi:10.1371/journal.pone.0011763.g007
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TCR TCRcd T cells circulate in peripheral blood (3–5% of
PBMNC) and express a peculiar TCR composed of c and d
chains, that recognize phosphoantigens. Most circulating TCRcd
T cells show the Vd2c9 rearrangement[17]. TCR Vd2c9 T cells
were obtained by stimulating PBMNC from normal donors with
5 uM n-bisphosphonate zoledronate (Novartis) for 7 days, as
described[58]. After stimulation, 92% of these cells were TCR
Vd2c9
+ T cells.
All these T cell populations were stimulated in vitro for 48 h in
RPMI 10% FBS at 37uC and 5% CO2 with anti-CD3 mAb
(OKT3, coated O.N. on 96 well plates) in the presence or absence
of sHLA-G (100 ng/ml) before being subjected to flow cytometric
analysis or in vitro migration assay.
Antibodies and flow cytometry
The following mAbs were used: anti-CXCR4 PE (clone #12G5),
anti-CXCR5 PE (clone #51505), anti-CCR7 APC (clone
#150503), anti-CCR6 PE (clone #53103), anti-CCR2 PE (clone
#48607), anti-CXCR3 FITC (clone #49801), anti-CXCR6 PE
(clone #56811), anti-CCR5 PE (clone #45531) (R&D System Inc.,
Minneapolis, MN, USA), anti-ICOS (clone # ANCC6C6-A3)
Santa Cruz Biotechnology), anti-CD4 FITC (clone# RPA-T4) and
anti-TCR cd PE (clone# GL3) (Becton Dickinson, NJ, USA).
Cells were stained with fluorochrome-conjugated mAbs or with
isotype and fluorochrome-matched control antibodies, and were
run on a FACSCalibur (Becton Dickinson). 10
4 events were
acquired and analyzed using the CellQuest software (Becton
Dickinson).
Blocking experiments
Blocking experiments were performed by stimulating cells as
described above, adding 1 mg/10
6 cells of blocking antibodies anti-
ILT2/CD85j (clone #292319) or anti-ILT4/CD85b (clone
#287219, R&D system) or isotype-matched control (Invitrogen,
CA, USA).
The specific SHP-2 phosphatase inhibitor PHPS1[28] was
purchased from Sigma Aldrich. Cells were cultured for 2 h at
37uC in the presence or absence of PHPS1 (10 mM), and then
stimulated as described above. Agonistic mAb (clone # F278) [59]
specific for ILT2/CD85j was kindly gifted by Dr. Daniela Pende
(IST, Genoa, Italy). Cells were stimulated with anti-CD3 mAb or
PHA for 72 h, in the presence or absence of 5 ml/10
6 cells of anti-
ILT2/CD85j monoclonal antibody.
Chemotaxis
Chemotaxis was investigated using 5 mm pore-size transwell
plates (Costar, Cambridge, MA) as reported[60]. Five 610
5 cells
were dispensed in the upper chamber, whereas chemokines or
medium alone were added to the lower chamber. CCL2, CCL8,
CCL21, CXCL10, CXCL11 (Immunotools, Friesoythe; Germany)
CXCL12 and CXCL13 (Abnova, Heidelberg, Germany) were
tested at 300 ng/mL[60] following preliminary titration experi-
ments. Plates were incubated 2 h at 37uC. Migrated cells were
collected and counted, and migration index was calculated as
follows: (nu of migrated cells/nu of dispensed cells*100). Migration
index obtained with medium alone was subtracted from each value.
Immunohistochemical staining of human tonsil
Immunohistochemical staining of tissue sections was performed
using the Envision System HRP mouse (Dako, Glostrup, Den-
mark). Briefly, 5 mm thick sections were cut from formalin fixed,
paraffin embedded blocks, deparaffinized with xylene and
rehydrated by passages through decreasing concentrations of
ethanol (from 100% to 80%). Endogenous peroxidase activity was
blocked by a 30 min incubation at room temperature with
methanol containing 3% H2O2. Tissue sections were then
incubated at 98uC for 40 min in citrate buffer (pH 6.0) for
antigen retrieval (ChemMate, Dako). After rinsing in Optimax
TM
Wash Buffer (Menarini Diagnostics, Firenze, Italy), tissue sections
were incubated 1 hour at room temperature with optimal amounts
of anti-HLA-G (1:25 MEM-G2, Exbio) or isotype control (mouse
IgG1, Invitrogen). Tissue sections were washed twice in Opti-
max
TM Wash Buffer and incubated for 30 min at room
temperature with Dako Envision System horse radish peroxidase
(HRP) Mouse. After washing in Optimax
TM Wash Buffer,
peroxidase activity was detected by incubating tissue sections for
6–10 min at room temperature with Dako Liquid DAB Substrate
Chromogen System (Dako). Tissue sections were counterstained
with Mayer’s hematoxylin (Sigma).
Western blot
Western blot analysis was performed on total extracts from
30*10
6 of CD4+ T cells stimulated as described above in presence
or absence of sHLA-G (100 ng/ml). Protein extracts were
obtained using Cell Extraction Buffer buffer (BioSource Interna-
tional, CA, USA) plus protease inhibitor cocktail (Sigma). Protein
quantification was performed by BCA assay (Sigma).
Total cell lysates were prepared and analyzed by western blot
analysis as described earlier[61]. Briefly, cells were lysed with Cell
Extraction Buffer (BioSource International) plus protease inhibitor
cocktail (Sigma). Protein lysates (70 ug per lane) were resolved on
SDS 12,5% polyacrylamide gels and were transferred to
nitrocellulose membranes. The membranes were then incubated
with the following mouse monoclonal antibodies: anti-Stat3, anti-
phospho Stat3, anti-Stat5, anti-phospho Stat5, anti b-arrestin1,
anti-phospho b-arrestin1, anti-SHP-2, anti phospho SHP-2, anti-
GSK3b, anti-phospo GSK-3b, anti PKCd, anti-phospo PKCd,
anti mTOR, anti-phospo mTOR, anti-p70 S6K, anti-phospo p70
S6K (Cell Signaling, MA, USA).
Peroxidase-conjugated goat anti-mouse and anti-rabbit poly-
clonal antisera were used as secondary reagents (Upstate/
Millipore, MA, USA and Santa Cruz Biotechnology, respectively).
Immune complexes were visualized with the use of a Super-
signal West Pico Chemiluminescent Substrate (Pierce, Rockford,
USA) according to the manufacturer’s instructions, and were
normalized to internal controls (a rabbit monoclonal antibody
against glyceraldehyde-3-phosphate dehydrogenase (Cell signal-
ing). Protein levels were quantified by scanning densitometry of
the autoradiography films using VersaDoc 3000 Gel Imaging
System (BioRad, CA, USA) and normalized over (ratio) the
housekeeping protein levels.
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